scispace - formally typeset
J

Jörn Drappa

Researcher at Cornell University

Publications -  5
Citations -  1083

Jörn Drappa is an academic researcher from Cornell University. The author has contributed to research in topics: Fas receptor & Lupus erythematosus. The author has an hindex of 5, co-authored 5 publications receiving 1066 citations.

Papers
More filters
Journal ArticleDOI

Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.

TL;DR: Patients with the Canale-Smith syndrome have mutations in Fas, which implicates this gene in the accumulation of lymphocytes and the autoimmunity characteristic of the syndrome.
Journal ArticleDOI

The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn.

TL;DR: Molecular cloning and nucleotide sequencing of a Fas-ETn chimeric cDNA suggested that the striking reduction in wild- type Fas mRNA levels and the presence of aberrant transcripts in MRL/lpr mice are most likely explained by the insertion of the ETn retrotransposon into an intron of the Fas gene and induction of alternative splicing involving the 5' ETn long terminal repeat.
Journal ArticleDOI

The apoptosis-1/Fas protein in human systemic lupus erythematosus.

TL;DR: The results reveal that, while APO-1/Fas may play an important role in the regulation of lymphocyte survival in SLE, no consistent defect in the expression or function of the receptor could be detected in these studies.
Journal ArticleDOI

The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations.

TL;DR: The P4 family provides a model of the complex genetic and functional interactions that are required for the development of a lupus-like syndrome and CD95 mutations are associated with loss of regulation of B lymphocytes, which predisposes to systemic autoimmunity including SLE.
Journal Article

Fas ligand expression and function in systemic lupus erythematosus.

TL;DR: Results indicate that no specific defects in FasL function are evident in the majority of SLE patients under the in vitro conditions tested, and the proportional reduction in Fas lupus erythematosus and rheumatoid arthritis patients following anti-CD3/IL-2 stimulation most likely reflects subtle differences in activation in patient-derived vs normal control T cells.